Cancellation of state registration. Spazmil-M

June 23, 2017
Trade names:
ICD-10:
XI.K50-K52.K51    Ulcerative colitis
XI.K50-K52.K52    Other non-infectious gastroenteritis and colitis
XI.K80-K87.K80    Gallstone disease [cholelithiasis]
XI.K80-K87.K82.8    Other specified diseases of the gallbladder
XI.K90-K93.K91.5    Postcholecystectomy syndrome
XIII.M20-M25.M25.5    Pain in the joint
XIII.M50-M54.M54.1    Radiculopathy
XIII.M50-M54.M54.3    Sciatica
XIII.M50-M54.M54.4    Lumbago with sciatica
XIII.M70-M79.M79.1    Myalgia
XIII.M70-M79.M79.2    Neuralgia and neuritis, unspecified
XIV.N20-N23.N23    Renal colic, unspecified
XIV.N30-N39.N30    Cystitis
XIV.N30-N39.N34    Urethritis and urethral syndrome
XIV.N40-N51.N41    Inflammatory diseases of the prostate
XIV.N70-N77.N70    Salpingitis and oophoritis
XIV.N70-N77.N72    Inflammatory disease of the cervix
XIV.N70-N77.N71.9    Inflammatory disease of uterus, unspecified
XIV.N70-N77.N73    Other inflammatory diseases of female pelvic organs
XIV.N80-N98.N94.4    Primary dysmenorrhea
XIV.N80-N98.N94.5    Secondary dysmenorrhea
XVIII.R10-R19.R10.4    Other and unspecified abdominal pain
XVIII.R50-R69.R52.0    Acute pain
XVIII.R50-R69.R52.2    Another constant pain
Spasmyl-M, spasmolytic, pain, pain treatment, abdominal pain, colic, spasm

The Ministry of Health of the Russian Federation in accordance with Article 29 of the Federal Law of 12.04.2010 No. 61-FZ "On the circulation of medicinal products" and on the basis of the submitted application No. 72599 (in No. 4023924 of September 15, 2016) and documents based on the results of the expert examinations, on the refusal to confirm the state registration of a medicinal product for medical use:

Spazmil-M (trade name of the medicinal product)

- (international non-proprietary, or grouping, or chemical name medicinal product)

pills (dosage form, dosage)

Sopharma AO, Bulgaria 1220, Sofia, 16 Iliensko Shosse Str., Bulgaria (name and address of the place of production)

in connection with the non-confirmation of the state registration of the medicinal product for medical use according to the results of the examination of the quality of the medicinal product and the examination of the relationship of the expected benefit to the possible risk of drug use.